+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 9 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the effects of elecoglipron compared with a placebo in adults with chronic kidney disease CKD, including those with and without type 2 diabetes mellitus T2DM. This Phase III, randomized, double-blind, placebo-controlled study includes participants who are receiving standard care treatments for CKD, including the SGLT2 inhibitor dapagliflozin. The study aims to determine whether elecoglipron can reduce the risk of kidney function decline, end-stage kidney disease, and mortality. Participants will be randomly assigned to receive either elecoglipron tablets or matching placebo tablets once daily. The study is multicenter and involves parallel groups. The treatment period and evaluation are event-driven and may last up to 4.5 years. Both study groups will continue their background therapies for CKD alongside the study medication or placebo. During the study, participants will be monitored regularly to assess kidney function, cardiovascular events, and overall health outcomes, including mortality. Researchers will measure sustained declines in estimated glomerular filtration rate eGFR, occurrence of end-stage kidney disease, cardiovascular death, heart failure hospitalizations, and other related outcomes. The study includes safety monitoring throughout the trial, which is expected to last until October 2030, with participant involvement potentially extending up to 4.5 years.

Age: 18Years +All GendersPhase 3
715 locations
E

Actively Recruiting

Researchers are evaluating whether tenecteplase helps adults recover from an acute ischemic stroke when given more than 4.5 hours after the person was last seen well. This study focuses on people who had a stroke caused by a clot blocking a brain blood vessel and have imaging showing brain tissue that can still be saved. Participants are excluded if they are planned for a procedure to remove the clot. Participants are randomly placed into two groups. One group receives a single intravenous injection of tenecteplase, while the other group receives standard medical care. The trial compares these treatments to see if tenecteplase improves recovery when given later than the usual 4.5-hour window after stroke onset. Participants stay in the study for about three months, including roughly one week in the hospital. They undergo seven clinical visits or exams, with the last two likely done remotely from home. Doctors assess recovery using a scale that measures disability and dependence in daily life. They also monitor health and any side effects to compare outcomes between the two groups.

Age: 18Years +All GendersPhase 3
257 locations
C

Actively Recruiting

Researchers are evaluating the accuracy of three different transthoracic needle aspiration TTNA techniquesjabbing-then-suction, suction-with-jabbing, and suction-onlyin patients suspected of having lung cancer. The study compares these methods to assess any differences in the quality of tumor samples obtained. The research is conducted with patients who have peripheral lung tumors attached to the chest wall and who are undergoing diagnostic testing. During hospitalization, patients will receive biopsies using each of the three TTNA techniques as well as a core needle biopsy, which serves as the gold standard. The biopsy procedures are done in an operating room under local anesthesia with supervision from an anesthesiologist. These biopsy techniques are standard procedures rather than experimental methods. After the biopsy, patients are monitored for at least 24 hours to watch for any possible complications. Participants will be involved during their hospital stay where multiple biopsy techniques are performed. The quality of samples from the different TTNA methods is assessed immediately after the biopsy procedure. Careful observation follows the biopsy to ensure patient safety. The total participation includes the biopsy procedure and the 24-hour observation period for any complications related to the biopsy.

Age: 18Years +All GendersPhase Not Applicable
1 location
H

Actively Recruiting

Researchers are evaluating whether home-based cardiac rehabilitation combined with a family empowerment approach can help patients recovering from acute coronary syndrome ACS. The study aims to find out if this method improves health-related quality of life and peak oxygen consumption peak Vo2 better than usual care. The trial includes adult patients aged 18 to 65 who have recently experienced ACS and have been discharged from the hospital between 3 months and 1 year prior to enrollment. Participants in the experimental group will undergo a 12-week home-based cardiac rehabilitation program that includes physical exercise, dietary management, smoking cessation, and stress management guided by educational materials and support from family and healthcare professionals. The intervention also involves regular monitoring of vital signs and exercise intensity based on a 6-minute walk test. The control group will receive usual care with education on medication adherence, exercise, smoking behavior, diet, and stress management in a single session. During the study, participants will perform prescribed walking exercises, follow diet and stress management plans, quit smoking, and comply with medication. They will visit a cardiologist at weeks 1, 6, and 12, and receive ongoing support from a nurse facilitator through video calls or home visits. Researchers will assess health-related quality of life and peak Vo2 at enrollment and after 12 weeks. Daily reports on diet, exercise, medication adherence, and heart rate during exercise will be collected and monitored to evaluate progress and safety.

Age: 18Years - 65YearsAll GendersPhase Not Applicable
2 locations
O

Actively Recruiting

Researchers are evaluating the experimental drug dovramilast in adults with moderate to severe acute or recurrent leprosy type 2 reaction, also known as erythema nodosum leprosum ENL. This phase 2 study compares the safety and effectiveness of two doses of dovramilast 100 mg and 150 mg against standard treatments such as prednisolone or thalidomide. The study aims to assess skin lesion improvement and the incidence of side effects over a 12-week period. Participants will be randomly assigned to receive either 100 mg or 150 mg of dovramilast or the standard of care treatment. The study is open-label, meaning both participants and researchers know which treatment is given. Treatment lasts 12 weeks, with outcomes measured at this timepoint, including the degree of skin lesion improvement and safety events. The study also monitors fever resolution, neuropathy changes, and recurrence of symptoms over up to 48 weeks. During the study, participants will undergo regular assessments including skin evaluations, symptom scoring using the ENLIST severity scale, and laboratory tests to monitor health and side effects. Researchers will track the need for rescue medication and measure drug exposure levels. Participants are expected to comply with all study procedures, including photographic assessments of skin lesions. The total participation time may extend to 48 weeks for some outcome measurements and safety monitoring.

Age: 18Years +All GendersPhase 2
6 locations
M

Actively Recruiting

This research aims to understand acute malnutrition in infants younger than 6 months admitted to pediatric or perinatology wards in hospitals across Indonesia. The study will observe how common acute malnutrition is in this age group and investigate the outcomes of nutrition therapy, including recovery, growth improvement, complications, and death. It also seeks to identify factors linked to successful nutrition treatment based on the 2023 WHO criteria. The study is observational and will not provide experimental treatments. Instead, it will collect detailed measurements of infants weight, length, head circumference, and mid-upper arm circumference at baseline, day 3, day 7, and weekly until hospital discharge. Information about birth history, feeding, illnesses, and nutrition therapy provided by treating doctors will be recorded. Data will be securely stored in a shared electronic database to ensure consistency across multiple hospitals participating in the network. Participants will be infants under 6 months diagnosed with acute malnutrition. Researchers will gather clinical data, anthropometric measurements, feeding details, and lab results during hospital stay. The study will monitor nutritional status changes up to 24 weeks or until discharge and track outcomes such as mortality. Results will help develop evidence-based feeding guidelines and improve clinical care for malnourished infants in Indonesia.

Age: 1Day - 6MonthsAll Genders
16 locations
R

Actively Recruiting

Researchers are evaluating the real-world effectiveness and safety of Nebilet4 nebivolol in adults with hypertension across seven Asian countries. This multinational, multicenter, observational, and prospective study aims to assess blood pressure changes, treatment adherence, quality of life, prescription patterns, and cardiovascular outcomes over up to three years. The study also compares Nebilet4 used alone versus in combination therapy and investigates the relationship between home and office blood pressure measurements. Participants include about 5,000 adults newly diagnosed with or having uncontrolled hypertension who have recently started Nebilet4 or been on it no more than two weeks. Patients are followed regularly for 12, 24, and 36 months, with blood pressure measured at each visit and home readings encouraged. The study collects data on medication dosing and frequency, adherence, and cardiovascular risk factors, while monitoring major adverse cardiac events such as heart attack, stroke, and cardiovascular death. During the study, participants complete questionnaires to assess quality of life and medication adherence every few months. Data are recorded through an electronic system ensuring consistency across sites. Researchers evaluate changes in systolic and diastolic blood pressure and the proportion achieving target blood pressure goals. Safety and any adverse events are documented, with follow-up visits extending up to three years to provide insights into the long-term management of hypertension with Nebilet4.

Age: 18Years - 100YearsAll Genders
49 locations
E

Actively Recruiting

Researchers are evaluating the safety and potential benefits of a single injection of allogeneic umbilical cord-derived mesenchymal stem cells UC-MSCs in adults aged 40 to 65 years with diabetic nephropathy, a kidney disease caused by diabetes. This study aims to find out if UC-MSC therapy is safe and well-tolerated when given directly into the kidneys and whether it can improve kidney function and reduce inflammation over a 12-month period. The trial is an open-label, single-arm study designed to explore these effects in patients who have chronic kidney disease stages III or IV related to diabetes. Participants will receive one intra-renal injection of UC-MSCs at a dose of 1 x 106 cells per kilogram of body weight. After the injection, they will be monitored over 12 months with scheduled visits at 1, 3, 6, 9, and 12 months to assess kidney function and inflammation. The treatment is given under imaging guidance to ensure accurate delivery. This trial does not include a comparison group and focuses on changes from baseline measurements following the intervention. During the study, participants will undergo evaluations of kidney function through estimated glomerular filtration rate eGFR, serum creatinine levels, and urine albumin-to-creatinine ratio. Inflammatory markers such as TNF-alpha and IL-10 will also be measured. Safety will be closely monitored by tracking any adverse events throughout the 12-month follow-up. The studys main outcome is to record the incidence of adverse events, with secondary outcomes focusing on changes in kidney function and inflammation markers over time.

Age: 30Years - 65YearsAll GendersPhase 1Phase 2
1 location
S

Actively Recruiting

This research aims to evaluate the effect of combining dlbs 3233 therapy with clomifen citrate compared to clomifen citrate alone on insulin resistance measured by HOMA-IR, follicle maturation, and menstrual cycle control in women diagnosed with Polycystic Ovary Syndrome PCOS. The study focuses on understanding how this combination therapy influences hormone levels and menstrual regulation, particularly in patients at Muhammadiyah Asri Medical Center Hospital. Participants will be randomly assigned to receive either the combination of dlbs 3233 and clomifen citrate or clomifen citrate alone. The study uses a quadruple masking design to compare the effectiveness of these treatments over a three-month period. The treatment effects will be monitored by measuring hormone levels such as serum AMH and evaluating follicle counts and sizes through ultrasound imaging. During the study, participants will have baseline assessments on the third day of their menstrual cycle, with follow-up evaluations at three months. These assessments include blood tests for HOMA-IR and AMH, as well as ultrasound examinations on day 12 of the menstrual cycle to monitor follicle development. Researchers will also track menstrual cycle regularity throughout the treatment period to measure the outcomes and safety of the therapies.

Age: 0 - 45YearsFEMALEEarly Phase 1
1 location